{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:17:04Z","timestamp":1792279024275,"version":"4.4.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005366","name":"University of Oslo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>This mini-review highlights the results of the SARAH trial, which evaluated the efficacy of sacubitril\/valsartan in preventing subclinical cardiac dysfunction in patients undergoing anthracycline-based chemotherapy. The trial demonstrated a significant reduction in GLS decline in the treatment group compared to placebo. The findings are discussed in context with other trials investigating neurohormonal blockade for the prevention of cancer therapy-related cardiac dysfunction.<\/jats:p>","DOI":"10.1007\/s10741-025-10495-1","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T08:53:55Z","timestamp":1739782435000},"page":"627-631","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The SARAH trial: more evidence on the role of neurohormonal blockers in prevention of anthracycline-induced cardiotoxicity"],"prefix":"10.1007","volume":"30","author":[{"given":"Albulena","family":"Mecinaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Vinje-Jakobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doan T. M.","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron L.","family":"Sverdlov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peder L.","family":"Myhre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"issue":"5","key":"10495_CR1","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaccao.2024.07.016","volume":"6","author":"M Camilli","year":"2024","unstructured":"Camilli M, Cipolla CM, Dent S, Minotti G, Cardinale DM (2024) Anthracycline cardiotoxicity in adult cancer patients: JACC: cardiooncology state-of-the-art review. JACC CardioOncol 6(5):655\u2013677","journal-title":"JACC CardioOncol"},{"issue":"1","key":"10495_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jaccao.2022.01.101","volume":"4","author":"T Omland","year":"2022","unstructured":"Omland T, Heck SL, Gulati G (2022) The role of cardioprotection in cancer therapy cardiotoxicity: JACC: cardiooncology state-of-the-art review. JACC CardioOncol 4(1):19\u201337","journal-title":"JACC CardioOncol"},{"issue":"23","key":"10495_CR3","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","volume":"114","author":"D Cardinale","year":"2006","unstructured":"Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M et al (2006) Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114(23):2474\u20132481","journal-title":"Circulation"},{"issue":"22","key":"10495_CR4","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","volume":"109","author":"D Cardinale","year":"2004","unstructured":"Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G et al (2004) Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109(22):2749\u20132754","journal-title":"Circulation"},{"issue":"8","key":"10495_CR5","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","volume":"63","author":"B Ky","year":"2014","unstructured":"Ky B, Putt M, Sawaya H, French B, Januzzi JL Jr, Sebag IA et al (2014) Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 63(8):809\u2013816","journal-title":"J Am Coll Cardiol"},{"key":"10495_CR6","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ejca.2018.02.005","volume":"94","author":"D Cardinale","year":"2018","unstructured":"Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M et al (2018) Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: the International CardioOncology Society-one trial. Eur J Cancer 94:126\u2013137","journal-title":"Eur J Cancer"},{"issue":"21","key":"10495_CR7","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1161\/CIRCULATIONAHA.123.064274","volume":"148","author":"PA Henriksen","year":"2023","unstructured":"Henriksen PA, Hall P, MacPherson IR, Joshi SS, Singh T, Maclean M et al (2023) Multicenter, prospective, randomized controlled trial of high-sensitivity cardiac troponin I-guided combination angiotensin receptor blockade and beta-blocker therapy to prevent anthracycline cardiotoxicity: the cardiac CARE trial. Circulation 148(21):1680\u20131690","journal-title":"Circulation"},{"issue":"1","key":"10495_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jaccao.2023.10.008","volume":"6","author":"A Mecinaj","year":"2024","unstructured":"Mecinaj A, Gulati G, Ree AH, Gravdehaug B, Rosjo H, Steine K et al (2024) Impact of the ESC cardio-oncology guidelines biomarker criteria on incidence of cancer therapy-related cardiac dysfunction. JACC CardioOncol 6(1):83\u201395","journal-title":"JACC CardioOncol"},{"issue":"10","key":"10495_CR9","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","volume":"4","author":"EK Oikonomou","year":"2019","unstructured":"Oikonomou EK, Kokkinidis DG, Kampaktsis PN, Amir EA, Marwick TH, Gupta D, Thavendiranathan P (2019) Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis. JAMA Cardiol 4(10):1007\u20131018","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10495_CR10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jcmg.2022.10.010","volume":"16","author":"T Negishi","year":"2023","unstructured":"Negishi T, Thavendiranathan P, Penicka M, Lemieux J, Murbraech K, Miyazaki S et al (2023) Cardioprotection using strain-guided management of potentially cardiotoxic cancer therapy: 3-year results of the SUCCOUR trial. JACC Cardiovasc Imaging 16(3):269\u2013278","journal-title":"JACC Cardiovasc Imaging"},{"issue":"41","key":"10495_CR11","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/eurheartj\/ehae574","volume":"45","author":"TH Marwick","year":"2024","unstructured":"Marwick TH, Dewar E, Nolan M, Shirazi M, Dias P, Wright L et al (2024) Strain surveillance during chemotherapy to improve cardiovascular outcomes: the SUCCOUR-MRI trial. Eur Heart J 45(41):4414\u20134424","journal-title":"Eur Heart J"},{"issue":"25","key":"10495_CR12","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1161\/CIRCULATIONAHA.121.054698","volume":"143","author":"SL Heck","year":"2021","unstructured":"Heck SL, Mecinaj A, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW et al (2021) Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): extended follow-up of a 2x2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Circulation 143(25):2431\u20132440","journal-title":"Circulation"},{"issue":"1","key":"10495_CR13","first-page":"33","volume":"7","author":"A Mecinaj","year":"2021","unstructured":"Mecinaj A, Gulati G, Heck SL, Holte E, Fagerland MW, Larsen AI et al (2021) Rationale and design of the prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial. Cardiooncology 7(1):33","journal-title":"Cardiooncology"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10495-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-025-10495-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10495-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T08:21:34Z","timestamp":1744359694000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-025-10495-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":13,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["10495"],"URL":"https:\/\/doi.org\/10.1007\/s10741-025-10495-1","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"6 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Myhre has received a lecture and advisory board honorarium from Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}